Neoplasms, Plasma Cell: all 2,314 studies
Page 20 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Efficacy Study of CYT997 in Multiple MyelomaTerminatedNCT00664378Phase 2
- Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple MyelomaCompletedNCT00657488Phase 2/3
- Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
- T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantTerminatedNCT00651716
- Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple MyelomaTerminatedNCT00644306Phase 3
- Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)CompletedNCT00642395Phase 2
- The Molecular Characterization of Multiple Myeloma at RelapseCompletedNCT00639054
- High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell TransplantTerminatedNCT00637767Phase 2
- Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)CompletedNCT00633542Phase 3
- Everolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00618345Phase 2
- Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00616720Phase 2
- Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple MyelomaTerminatedNCT00609817Phase 1
- Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantCompletedNCT00602706Phase 1/2
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
- Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose MelphalanTerminatedNCT00602147
- Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCTCompletedNCT00599495Phase 2
- Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT00594126Phase 1
- A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple MyelomaCompletedNCT00592579Phase 2
- Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00590603Phase 1
- High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple MyelomaCompletedNCT00586014Phase 2
- Therapeutic Research in Multiple MyelomaCompletedNCT00572338
- Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose ChemotherapyStatus unknownNCT00571168Phase 3
- Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple MyelomaCompletedNCT00570180Phase 2
- Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00568880Phase 1
- MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative ConditioningCompletedNCT00564200Phase 2
- A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma PatientsCompletedNCT00561743Phase 2
- Pethema Multiple Myeloma 2000CompletedNCT00560053Phase 3
- Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple MyelomaCompletedNCT00555100Phase 1
- Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT00551928Phase 3
- Phase I Study for Safety and Efficacy of P276-00 in Subjects With MyelomaWithdrawnNCT00547404Phase 1
- Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 YearsStatus unknownNCT00546988Phase 3
- A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First RelapseCompletedNCT00546780Phase 3
- A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple MyelomaCompletedNCT00545519Phase 1
- Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.CompletedNCT00532675Phase 1
- Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple MyelomaCompletedNCT00532389Phase 1
- High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple MyelomaStatus unknownNCT00526734Phase 2
- Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT00525447Phase 1
- Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other DiseaseCompletedNCT00521430Not applicable
- A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple MyelomaWithdrawnNCT00516191Phase 1/2
- A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCompletedNCT00514371Phase 2/3
- Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaCompletedNCT00511082Phase 1
- Etiology of Multiple Myeloma: A Case-Control StudyStatus unknownNCT00505999
- Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for MyelomaCompletedNCT00504634Phase 2
- Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple MyelomaWithdrawnNCT00504101Phase 1
- Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple MyelomaWithdrawnNCT00503763Phase 2
- Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With CancerWithdrawnNCT00499668Not applicable
- Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple MyelomaCompletedNCT00499577Phase 1/2
- A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)TerminatedNCT00499239Phase 1/2
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple MyelomaCompletedNCT00482846Phase 1
- Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With CancerStatus unknownNCT00482716Phase 3
- Bevacizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00482495Phase 2
- Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone PainCompletedNCT00482378Phase 1/2
- A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for MyelosuppressionCompletedNCT00482261Phase 2
- QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of ProgressionCompletedNCT00480363Phase 3
- Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00478075Phase 1/2
- Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00477815Phase 1
- Long-Term Follow Up Study for AMD3100 PatientsCompletedNCT00476294
- Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1
- Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesTerminatedNCT00473551Phase 1
- Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell TransplantTerminatedNCT00469820Phase 1
- Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity ConditioningCompletedNCT00466674Phase 2
- GEM05 for Patients With Multiple Myeloma Under 65 YearsCompletedNCT00461747Phase 3
- The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple MyelomaCompletedNCT00459069Phase 1
- Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple MyelomaCompletedNCT00458653Phase 1
- A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaCompletedNCT00457782Phase 1
- Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple MyelomaCompletedNCT00452569Phase 3
- GEM05 for Patients With Multiple Myeloma More Than 65 Years OldCompletedNCT00443235Phase 3
- Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple MyelomaCompletedNCT00440635
- Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple MyelomaStatus unknownNCT00438841Phase 2
- A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed MyelomaStatus unknownNCT00431990Phase 1/2
- An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple MyelomaCompletedNCT00431769Phase 2
- A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple MyelomaTerminatedNCT00431340Phase 2
- Maintenance Therapy Using Lenalidomide in MyelomaCompletedNCT00430365Phase 3
- Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple MyelomaCompletedNCT00425347Phase 1
- Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior YearCompletedNCT00424983Phase 1
- Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal MetastasesCompletedNCT00424242Early Phase 1
- Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseNo longer availableNCT00423826
- Phase I/II Study of hLL1 in Multiple MyelomaCompletedNCT00421525Phase 1/2
- Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma PatientsCompletedNCT00417911Phase 3
- Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney FailureCompletedNCT00416897Phase 3
- A Study of Bortezomib as Consolidation Therapy in Patients With Multiple MyelomaCompletedNCT00416273Phase 3
- Consolidation Therapy With Bortezomib in Elderly Patients With Multiple MyelomaCompletedNCT00416208Phase 3
- Hematopoietic Stem Cell Transplantation in MyelomaStatus unknownNCT00415987Phase 2/3
- Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple MyelomaCompletedNCT00415064Phase 1
- Study of Azacitidine to Treat Relapsed or Refractory Multiple MyelomaTerminatedNCT00412919Phase 2
- A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 1
- Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantCompletedNCT00410657Phase 2
- Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma PatientsCompletedNCT00406978Phase 1/2
- An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT00402181Phase 2
- Bortezomib-Dexamethasone-Doxorubicin-StudyCompletedNCT00401804Phase 2
- Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma PatientsCompletedNCT00401011Phase 1/2
- ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor CellsCompletedNCT00400556Phase 1
- Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.CompletedNCT00399867Phase 2
- Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00398515Phase 1
- Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple MyelomaCompletedNCT00396045Phase 1/2
- VELCADEXA: Velcade and Dexamethasone in Multiple MyelomaCompletedNCT00391157Phase 2
- Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to TreatmentStatus unknownNCT00389701Phase 2
- Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell TransplantCompletedNCT00388999Phase 1
- Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.CompletedNCT00388635Phase 1/2